IGC Pharma, Inc.
IGC
$0.3228
$0.01645.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 257.00K | 412.00K | 272.00K | 295.00K | 204.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 257.00K | 412.00K | 272.00K | 295.00K | 204.00K |
| Cost of Revenue | 153.00K | 214.00K | 109.00K | 124.00K | 71.00K |
| Gross Profit | 104.00K | 198.00K | 163.00K | 171.00K | 133.00K |
| SG&A Expenses | 1.13M | 1.04M | 1.64M | 2.23M | 2.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.14M | 2.17M | 2.64M | 3.21M | 3.20M |
| Operating Income | -1.88M | -1.76M | -2.37M | -2.92M | -3.00M |
| Income Before Tax | -1.83M | -1.72M | -2.38M | -2.89M | -5.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.83M | -1.72M | -2.38M | -2.89M | -5.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.83M | -1.72M | -2.38M | -2.89M | -5.59M |
| EBIT | -1.88M | -1.76M | -2.37M | -2.92M | -3.00M |
| EBITDA | -1.72M | -1.62M | -2.21M | -2.75M | -2.84M |
| EPS Basic | -0.02 | -0.02 | -0.03 | -0.04 | -0.09 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 |
| EPS Diluted | -0.02 | -0.02 | -0.03 | -0.04 | -0.09 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 77.63M | 76.01M | 72.81M | 64.24M | 63.73M |
| Average Diluted Shares Outstanding | 77.63M | 76.01M | 72.81M | 64.24M | 63.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
